# Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia

Study · id `cardio:ct-nct03409744` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03409744](<https://clinicaltrials.gov/study/NCT03409744>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03409744

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 116 participants.

## Technical summary

Registry record NCT03409744. Allocation not applicable; no masking; primary purpose treatment. Start 2018-03-13 (actual); primary completion 2023-04-13 (actual). Results posted on 2024-04-30.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 116 participants (enrolled count; ClinicalTrials.gov record NCT03409744, source copy `cardio:ctgov-nct03409744-2025-04-08`, retrieved 2026-10-31)
- Started: 2018-03-13 (actual) (ClinicalTrials.gov record NCT03409744, source copy `cardio:ctgov-nct03409744-2025-04-08`, retrieved 2026-10-31)
- Primary completion: 2023-04-13 (actual) (ClinicalTrials.gov record NCT03409744, source copy `cardio:ctgov-nct03409744-2025-04-08`, retrieved 2026-10-31)
- Completion: 2023-04-13 (actual) (ClinicalTrials.gov record NCT03409744, source copy `cardio:ctgov-nct03409744-2025-04-08`, retrieved 2026-10-31)
- Results first posted: 2024-04-30 (ClinicalTrials.gov record NCT03409744, source copy `cardio:ctgov-nct03409744-2025-04-08`, retrieved 2026-10-31)
- Countries: United States; Australia; Austria; Canada; Czechia; France; Greece; Italy; Japan; Netherlands; South Africa; Ukraine (ClinicalTrials.gov record NCT03409744, source copy `cardio:ctgov-nct03409744-2025-04-08`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03409744-2025-04-08`, retrieved 2026-10-31)

## The registry's words

- Brief title: Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia
- Condition: Homozygous Familial Hypercholesterolemia
- Intervention (Drug): evinacumab
- Lead sponsor: Regeneron Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: Familial hypercholesterolemia (`cardio:familial-hypercholesterolemia`)
- Registry lists this organization as the lead sponsor: Regeneron Pharmaceuticals (`cardio:org-regeneron-pharmaceuticals`)

## Provenance

Content hash: 179ed56aa7c6e1086627e5a9d247ccc66dd35ef58c4bc938e1a51dfb2125d1b7
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
